{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:18:08Z","timestamp":1793013488506,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04644-8","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:31:58Z","timestamp":1768887118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Double-seronegative myasthenia gravis: clinical characteristics, treatment, and outcomes \u2013 a systematic review of case reports and case series"],"prefix":"10.1186","volume":"26","author":[{"given":"Aseel","family":"Abuhammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-2365","authenticated-orcid":false,"given":"Mohammed","family":"Ayyad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram","family":"Albandak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salsabeel M.","family":"AbuKhalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arein","family":"Madia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basema","family":"Qawasma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad M.","family":"AbuKhalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan Abu","family":"Thraiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Zuaiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith","family":"Alamleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"4644_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/s-0037-1618591","volume":"49","author":"T Tozawa","year":"2018","unstructured":"Tozawa T, Nishimura A, Ueno T, et al. A 5-Year Follow-Up of Triple-Seronegative myasthenia Gravis successfully treated with tacrolimus therapy. Neuropediatrics. 2018;49:200\u20133.","journal-title":"Neuropediatrics"},{"key":"4644_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","volume":"259","author":"A Pevzner","year":"2012","unstructured":"Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia Gravis. J Neurol. 2012;259:427\u201335.","journal-title":"J Neurol"},{"key":"4644_CR3","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.2169\/internalmedicine.55.7030","volume":"55","author":"G Beck","year":"2016","unstructured":"Beck G, Yabumoto T, Baba K, et al. Double seronegative myasthenia Gravis with Anti-LRP4 antibodies presenting with dropped head and acute respiratory insufficiency. Intern Med. 2016;55:3361\u20133.","journal-title":"Intern Med"},{"key":"4644_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajem.2021.03.005","volume":"46","author":"DN Lipe","year":"2021","unstructured":"Lipe DN, Galvis-Carvajal E, Rajha E, et al. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome. Am J Emerg Med. 2021;46:51\u20135.","journal-title":"Am J Emerg Med"},{"key":"4644_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jns.2014.07.060","volume":"346","author":"I Basta","year":"2014","unstructured":"Basta I, Pekmezovic T, Peric S, et al. Extrathymic malignancies in a defined cohort of patients with myasthenia Gravis. J Neurol Sci. 2014;346:80\u20134.","journal-title":"J Neurol Sci"},{"key":"4644_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:71.","journal-title":"BMJ"},{"key":"4644_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","volume":"1413","author":"H Murai","year":"2018","unstructured":"Murai H, Utsugisawa K, Nagane Y, et al. Rationale for the clinical guidelines for myasthenia Gravis in Japan. Ann N Y Acad Sci. 2018;1413:35\u201340.","journal-title":"Ann N Y Acad Sci"},{"key":"4644_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7453\/gahmj.2013.008","volume":"2","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Heal Med. 2013;2:38\u201343.","journal-title":"Glob Adv Heal Med"},{"key":"4644_CR9","doi-asserted-by":"publisher","unstructured":"Lee SY, Gill A, Jung SM. Pure red cell aplasia and seronegative myasthenia gravis in association with thymoma. J Community Hosp Intern Med Perspect. 2020;10(3):238\u201341. https:\/\/doi.org\/10.1080\/20009666.2020.1770019.","DOI":"10.1080\/20009666.2020.1770019"},{"key":"4644_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/WNO.0000000000000499","volume":"37","author":"JM Kruger","year":"2017","unstructured":"Kruger JM, Karussis D, Zisimopoulou P, et al. Low-Density lipoprotein Receptor-Related protein 4-Positive myasthenia Gravis in a Double-Seronegative, Electromyography-Negative patient. J Neuroophthalmol. 2017;37:285\u20136.","journal-title":"J Neuroophthalmol"},{"key":"4644_CR11","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2169\/internalmedicine.1956-18","volume":"58","author":"A Onda","year":"2019","unstructured":"Onda A, Miyagawa S, Takahashi N, et al. Pembrolizumab-induced ocular myasthenia Gravis with Anti-titin antibody and necrotizing myopathy. Intern Med. 2019;58:1635\u20138.","journal-title":"Intern Med"},{"key":"4644_CR12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2169\/internalmedicine.3828-19","volume":"59","author":"S Aoki","year":"2020","unstructured":"Aoki S, Nagashima K, Furuta M, et al. Anti-LRP4 Antibody-associated myasthenia Gravis with a rare complication of thymoma successfully treated by thymectomy. Intern Med. 2020;59:1219\u201322.","journal-title":"Intern Med"},{"key":"4644_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1752-1947-8-2","volume":"8","author":"D Dan","year":"2014","unstructured":"Dan D, Bart PA, Novy J, et al. Double seronegative myasthenia Gravis with antiphospholipid syndrome: a case report. J Med Case Rep. 2014;8:2.","journal-title":"J Med Case Rep"},{"key":"4644_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/mus.27079","volume":"63","author":"N Hayashi","year":"2021","unstructured":"Hayashi N, Sone J, Fukami Y, et al. Severe myasthenia Gravis with anti-LRP4 antibodies and hodgkin lymphoma. Muscle Nerve. 2021;63:2\u20134.","journal-title":"Muscle Nerve"},{"key":"4644_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1055\/s-0036-1579624","volume":"6","author":"C Townsel","year":"2016","unstructured":"Townsel C, Keller R, Johnson K, et al. Seronegative maternal ocular myasthenia Gravis and delayed transient neonatal myasthenia Gravis. AJP Rep. 2016;6:133\u20136.","journal-title":"AJP Rep"},{"key":"4644_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.neurol.2011.07.017","volume":"168","author":"I Marouani","year":"2012","unstructured":"Marouani I, Kraoua I, Benrhouma H, et al. Seronegative myasthenia Gravis with bladder dysfunction. Rev Neurol (Paris). 2012;168:299\u2013300.","journal-title":"Rev Neurol (Paris)"},{"key":"4644_CR17","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2169\/internalmedicine.54.3363","volume":"54","author":"K Niimi","year":"2015","unstructured":"Niimi K, Nagata E, Murata N, et al. Lung cancer associated with seronegative myasthenia Gravis. Intern Med. 2015;54:1381\u20134.","journal-title":"Intern Med"},{"key":"4644_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jns.2010.12.013","volume":"302","author":"A Rigamonti","year":"2011","unstructured":"Rigamonti A, Lauria G, Piamarta F, et al. Thymoma-associated myasthenia Gravis without acetylcholine receptor antibodies. J Neurol Sci. 2011;302:112\u20133.","journal-title":"J Neurol Sci"},{"key":"4644_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jcjo.2017.04.012","volume":"52","author":"DC Sousa","year":"2017","unstructured":"Sousa DC, Viana P, Leal I, et al. Ophthalmoparesis and unilateral finger flexor muscle weakness in seronegative myasthenia Gravis. Can J Ophthalmol. 2017;52:213\u20136.","journal-title":"Can J Ophthalmol"},{"key":"4644_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jns.2014.09.013","volume":"346","author":"G Tsivgoulis","year":"2014","unstructured":"Tsivgoulis G, Dervenoulas G, Kokotis P, et al. Double seronegative myasthenia Gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms. J Neurol Sci. 2014;346:328\u201330.","journal-title":"J Neurol Sci"},{"key":"4644_CR21","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.nmd.2013.03.013","volume":"23","author":"V Zouvelou","year":"2013","unstructured":"Zouvelou V, Zisimopoulou P, Rentzos M, et al. Double seronegative myasthenia Gravis with anti-LRP 4 antibodies. Neuromuscul Disord. 2013;23:568\u201370.","journal-title":"Neuromuscul Disord"},{"key":"4644_CR22","first-page":"06","volume":"9","author":"R Mandaliya","year":"2015","unstructured":"Mandaliya R, Kulandaivel K, Nowotarski N, et al. A challenging diagnosis of fluctuating dyspnea: myasthenia Gravis. J Clin Diagn Res. 2015;9:06\u20138.","journal-title":"J Clin Diagn Res"},{"key":"4644_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000508815","volume":"11","author":"R Arnon","year":"2020","unstructured":"Arnon R, Yahalomi T, Rozen-Knisbacher I, et al. Ocular myasthenia Gravis with severe blepharitis and ocular surface disease: A case report. Case Rep Ophthalmol. 2020;11:322\u20139.","journal-title":"Case Rep Ophthalmol"},{"key":"4644_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","volume":"27","author":"NL Gonzalez","year":"2017","unstructured":"Gonzalez NL, Puwanant A, Lu A, et al. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017;27:266\u20138.","journal-title":"Neuromuscul Disord"},{"key":"4644_CR25","doi-asserted-by":"publisher","first-page":"e00355","DOI":"10.1002\/rcr2.355","volume":"6","author":"M Hibino","year":"2018","unstructured":"Hibino M, Maeda K, Horiuchi S, et al. Pembrolizumab-induced myasthenia Gravis with myositis in a patient with lung cancer. Respirol Case Rep. 2018;6:e00355.","journal-title":"Respirol Case Rep"},{"key":"4644_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ccr3.747","volume":"5","author":"T Ishiguro","year":"2016","unstructured":"Ishiguro T, Kagiyama N, Kawate E, et al. Development of myasthenia Gravis 8 years after interstitial lung disease associated with antisynthetase (anti-EJ antibody) syndrome. Clin Case Rep. 2016;5:61\u20135.","journal-title":"Clin Case Rep"},{"key":"4644_CR27","doi-asserted-by":"publisher","first-page":"e232920","DOI":"10.1136\/bcr-2019-232920","volume":"13","author":"PJ Leaver","year":"2020","unstructured":"Leaver PJ, Jang HS, Vernon ST, et al. Immune checkpoint inhibitor-mediated myasthenia Gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease. BMJ Case Rep. 2020;13:e232920.","journal-title":"BMJ Case Rep"},{"key":"4644_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.nmd.2014.10.004","volume":"25","author":"D Renard","year":"2015","unstructured":"Renard D, Hedayat A, Gagnard C. Isolated laryngeal myasthenia Gravis for 26 years. Neuromuscul Disord. 2015;25:153\u20134.","journal-title":"Neuromuscul Disord"},{"key":"4644_CR29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fneur.2018.00150","volume":"9","author":"V Montes","year":"2018","unstructured":"Montes V, Sousa S, Pita F, et al. Myasthenia Gravis induced by ipilimumab in a patient with metastatic melanoma. Front Neurol. 2018;9:150.","journal-title":"Front Neurol"},{"key":"4644_CR30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.semarthrit.2013.12.005","volume":"43","author":"JJ Paik","year":"2014","unstructured":"Paik JJ, Corse AM, Mammen AL. The co-existence of myasthenia Gravis in patients with myositis: a case series. Semin Arthritis Rheum. 2014;43:792\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"4644_CR31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/WNO.0000000000000534","volume":"37","author":"RM Rautenbach","year":"2017","unstructured":"Rautenbach RM, Pillay K, Murray ADN, et al. Extraocular muscle findings in myasthenia Gravis associated Treatment-Resistant ophthalmoplegia. J Neuroophthalmol. 2017;37:414\u20137.","journal-title":"J Neuroophthalmol"},{"key":"4644_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12883-019-1482-4","volume":"19","author":"S Wang","year":"2019","unstructured":"Wang S, Jiang B, Li Y, et al. A case report of disseminated nocardiosis with ocular involvement in a myasthenia Gravis patient and literature review. BMC Neurol. 2019;19:243.","journal-title":"BMC Neurol"},{"key":"4644_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/mus.26124","volume":"58","author":"CJJ Yeo","year":"2018","unstructured":"Yeo CJJ, Pleitez MY. Eculizumab in refractory myasthenic crisis. Muscle Nerve. 2018;58:13\u20135.","journal-title":"Muscle Nerve"},{"key":"4644_CR34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2217\/imt-2019-0106","volume":"11","author":"C Yuen","year":"2019","unstructured":"Yuen C, Fleming G, Meyers M, et al. Myasthenia Gravis induced by avelumab. Immunotherapy. 2019;11:1181\u20135.","journal-title":"Immunotherapy"},{"key":"4644_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/CJI.0000000000000278","volume":"42","author":"O Becquart","year":"2019","unstructured":"Becquart O, Lacotte J, Malissart P, et al. Myasthenia Gravis induced by immune checkpoint inhibitors. J Immunother. 2019;42:309\u201312.","journal-title":"J Immunother"},{"key":"4644_CR36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.nmd.2009.09.005","volume":"19","author":"P Caliandro","year":"2009","unstructured":"Caliandro P, Evoli A, St\u00e5lberg E, et al. The difficulty in confirming clinical diagnosis of myasthenia Gravis in a seronegative patient: a possible neurophysiological approach. Neuromuscul Disord. 2009;19:825\u20137.","journal-title":"Neuromuscul Disord"},{"key":"4644_CR37","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.3346\/jkms.2022.37.e50","volume":"37","author":"MA Lee","year":"2022","unstructured":"Lee MA, Lee C. Early-Onset myasthenia Gravis following COVID-19 vaccination. J Korean Med Sci. 2022;37:e50.","journal-title":"J Korean Med Sci"},{"key":"4644_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fonc.2019.00084","volume":"9","author":"JM Werner","year":"2019","unstructured":"Werner JM, Schweinsberg V, Schroeter M, et al. Successful treatment of myasthenia Gravis following PD-1\/CTLA-4 combination checkpoint Blockade in a patient with metastatic melanoma. Front Oncol. 2019;9:84.","journal-title":"Front Oncol"},{"key":"4644_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10072-010-0358-6","volume":"31","author":"G Bigliardi","year":"2010","unstructured":"Bigliardi G, Mandrioli J, Valzania F, et al. Primary progressive multiple sclerosis and generalized myasthenia gravis: an uncommon association. Neurol Sci. 2010;31:833\u20136.","journal-title":"Neurol Sci"},{"key":"4644_CR40","doi-asserted-by":"publisher","first-page":"106045","DOI":"10.1016\/j.clineuro.2020.106045","volume":"196","author":"S Singh","year":"2020","unstructured":"Singh S, Govindarajan R. COVID-19 and generalized myasthenia Gravis exacerbation: A case report. Clin Neurol Neurosurg. 2020;196:106045.","journal-title":"Clin Neurol Neurosurg"},{"key":"4644_CR41","doi-asserted-by":"publisher","first-page":"e231296","DOI":"10.1136\/bcr-2019-231296","volume":"12","author":"G Saluja","year":"2019","unstructured":"Saluja G, Samdani A, Bhatia P. Importance of clinical tests in ocular myasthenia. BMJ Case Rep. 2019;12:e231296.","journal-title":"BMJ Case Rep"},{"key":"4644_CR42","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s10072-021-05823-w","volume":"43","author":"CL Rodrigues","year":"2022","unstructured":"Rodrigues CL, de Freitas HC, Lima PRO, et al. Myasthenia Gravis exacerbation and myasthenic crisis associated with COVID- 19: case series and literature review. Neurol Sci. 2022;43:2271\u20136.","journal-title":"Neurol Sci"},{"key":"4644_CR43","first-page":"e27826","volume":"14","author":"N Yoshioka","year":"2022","unstructured":"Yoshioka N, Naito Y, Sano K, et al. Seronegative ocular myasthenia Gravis in an older woman with transient Dizziness and diplopia. Cureus. 2022;14:e27826.","journal-title":"Cureus"},{"key":"4644_CR44","doi-asserted-by":"publisher","first-page":"6863938","DOI":"10.1155\/2017\/6863938","volume":"2017","author":"R Sharief","year":"2017","unstructured":"Sharief R, Miodovnik A, Motaghedi R. Seronegative myasthenia Gravis, as a rare autoimmune condition in Turner syndrome. Case Rep Pediatr. 2017;2017:6863938.","journal-title":"Case Rep Pediatr"},{"key":"4644_CR45","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.nmd.2013.03.014","volume":"23","author":"D Renard","year":"2013","unstructured":"Renard D, Cornillet L, Castelnovo G. Myocardial infarction after rituximab infusion. Neuromuscul Disord. 2013;23:599\u2013601.","journal-title":"Neuromuscul Disord"},{"key":"4644_CR46","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.nmd.2008.06.368","volume":"18","author":"L Maggi","year":"2008","unstructured":"Maggi L, Andreetta F, Antozzi C, et al. Two cases of thymoma-associated myasthenia Gravis without antibodies to the acetylcholine receptor. Neuromuscul Disord. 2008;18:678\u201380.","journal-title":"Neuromuscul Disord"},{"key":"4644_CR47","doi-asserted-by":"publisher","first-page":"e16022","DOI":"10.1111\/ene.16022","volume":"31","author":"R Martinez-Harms","year":"2024","unstructured":"Martinez-Harms R, Barnett C, Alcantara M, et al. Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia Gravis. Eur J Neurol. 2024;31:e16022.","journal-title":"Eur J Neurol"},{"key":"4644_CR48","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","volume":"73","author":"E Cort\u00e9s-Vicente","year":"2016","unstructured":"Cort\u00e9s-Vicente E, Gallardo E, Mart\u00ednez M\u00c1, et al. Clinical characteristics of patients with Double-Seronegative myasthenia Gravis and antibodies to cortactin. JAMA Neurol. 2016;73:1099\u2013104.","journal-title":"JAMA Neurol"},{"key":"4644_CR49","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1007\/s00415-022-11458-4","volume":"270","author":"YN Kwon","year":"2023","unstructured":"Kwon YN, Woodhall M, Sung JJ, et al. Clinical pitfalls and serological diagnostics of musk myasthenia Gravis. J Neurol. 2023;270:1478\u201386.","journal-title":"J Neurol"},{"key":"4644_CR50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia Gravis. BMC Neurol. 2010;10:46.","journal-title":"BMC Neurol"},{"key":"4644_CR51","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ. Generalized myasthenia gravis: Classification, clinical Presentation, natural History, and epidemiology. Neurol Clin. 2018;36:253\u201360.","journal-title":"Neurol Clin"},{"key":"4644_CR52","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00415-009-5091-9","volume":"256","author":"A Citterio","year":"2009","unstructured":"Citterio A, Beghi E, Millul A, et al. Risk factors for tumor occurrence in patients with myasthenia Gravis. J Neurol. 2009;256:1221\u20137.","journal-title":"J Neurol"},{"key":"4644_CR53","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/ene.14730","volume":"28","author":"J Verwijst","year":"2021","unstructured":"Verwijst J, Westerberg E, Punga AR. Cancer in myasthenia Gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: A Swedish nationwide register study. Eur J Neurol. 2021;28:1706\u201315.","journal-title":"Eur J Neurol"},{"key":"4644_CR54","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","volume":"11","author":"YT Huang","year":"2020","unstructured":"Huang YT, Chen YP, Lin WC, et al. Immune checkpoint Inhibitor-Induced myasthenia Gravis. Front Neurol. 2020;11:634.","journal-title":"Front Neurol"},{"key":"4644_CR55","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/jcm12010130","volume":"12","author":"C Marco","year":"2022","unstructured":"Marco C, Sim\u00f3 M, Alemany M, et al. Myasthenia Gravis induced by immune checkpoint inhibitors: an emerging neurotoxicity in Neuro-Oncology practice: case series. J Clin Med. 2022;12:130.","journal-title":"J Clin Med"},{"key":"4644_CR56","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7:319.","journal-title":"J Immunother Cancer"},{"key":"4644_CR57","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jocn.2019.11.038","volume":"71","author":"TRA Ozarczuk","year":"2020","unstructured":"Ozarczuk TRA, Prentice DA, Kho LK, et al. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy. J Clin Neurosci. 2020;71:271\u20132.","journal-title":"J Clin Neurosci"},{"key":"4644_CR58","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023\u201336.","journal-title":"Lancet Neurol"},{"key":"4644_CR59","first-page":"596981","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG Management.Front. Neurol. 2020;11:596981.","journal-title":"Neurol"},{"issue":"2","key":"4644_CR60","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","volume":"9","author":"E Cort\u00e9s-Vicente","year":"2022","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Pla-Junca F, Rojas-Garcia R, Paradas C, Sevilla T, et al. Drug-refractory myasthenia gravis: clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol. 2022;9(2):122\u201331. https:\/\/doi.org\/10.1002\/acn3.51492. https:\/\/pubmed.ncbi.nlm.nih.gov\/35080153\/. Epub 2022 Jan 26. PMID: 35080153; PMCID: PMC8862423.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"4644_CR61","doi-asserted-by":"publisher","first-page":"e16022","DOI":"10.1111\/ene.16022","volume":"31","author":"R Martinez-Harms","year":"2024","unstructured":"Martinez-Harms R, Barnett C, Alcantara M, Bril V. Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis. Eur J Neurol. 2024;31(1):e16022. https:\/\/doi.org\/10.1111\/ene.16022. https:\/\/pubmed.ncbi.nlm.nih.gov\/37531447\/. Epub 2023 Aug 16. PMID: 37531447; PMCID: PMC11235949.","journal-title":"Eur J Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04644-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04644-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04644-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:03:19Z","timestamp":1770987799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04644-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4644"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04644-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review of previously published literature and did not involve new studies with human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}